Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@AnnieTyzak Eye issues? Never supported with strong evidence.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
8,12 mil
0
O conteúdo apresentado nesta página é fornecido por terceiros. Salvo indicação em contrário, a OKX não é o autor dos artigos citados e não reivindica quaisquer direitos de autor nos materiais. O conteúdo é fornecido apenas para fins informativos e não representa a opinião da OKX. Não se destina a ser um endosso de qualquer tipo e não deve ser considerado conselho de investimento ou uma solicitação para comprar ou vender ativos digitais. Na medida em que a IA generativa é utilizada para fornecer resumos ou outras informações, esse mesmo conteúdo gerado por IA pode ser impreciso ou inconsistente. Leia o artigo associado para obter mais detalhes e informações. A OKX não é responsável pelo conteúdo apresentado nos sites de terceiros. As detenções de ativos digitais, incluindo criptomoedas estáveis e NFTs, envolvem um nível de risco elevado e podem sofrer grandes flutuações. Deve considerar cuidadosamente se o trading ou a detenção de ativos digitais é adequado para si à luz da sua condição financeira.